1333262-65-9

Upstream product

• 321-23-3 4-bromo-2-fluoronitrobenzene 
• 302800-13-1 5-bromo-N-methyl-2-nitroaniline 
• 337915-79-4 4-bromo-N²-methylbenzene-1,2-diamine 
• 55783-43-2 5-bromo-N¹-methylbenzene-1,2-diamine dihydrochloride 

Downstream Products

• 1333262-64-8 2-[1-(cyclopropylmethyl)-3-methyl-2,2-dioxido-1,3-dihydro-2,1,3-benzothiadiazol-5-yl]benzonitrile 
• 1333262-67-1 2-[1-(cyclopropylmethyl)-3-methyl-2,2-dioxido-1,3-dihydro-2,1,3-benzothiadiazol-5-yl]-6-fluorobenzonitrile 

Relevant academic research and scientific papers

PDE 10a Inhibitors for the Treatment of Type II Diabetes

Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R1, R2, L, and Q are defined herein.

POSITIVE ALLOSTERIC MODULATORS OF MGLUR2

The present invention is directed to 5-substituted 1,3-dihydro-2,1,3-benzothiadiazole 2,2-dioxide and 1,3-dihydro[1,2,5]thiadiazolo[3,4-b]pyridine 2,2,-dioxide derivatives which are potentiators of metabotropic glutamate receptors, particularly the mGluR2 receptor, and which are useful in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which metabotropic glutamate receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which metabotropic glutamate receptors are involved